NOVO NORDISK
Oral Semaglutide Innovation Story
Background: Developed by Novo Nordisk, oral semaglutide is the first oral GLP-1 receptor agonist (RA) for the treatment of type 2 diabetes. The journey to make semaglutide available in a pill has taken 15 years. This is the story of how Novo Nordisk achieved this.
Creative concept: The oral semaglutide 'lab to life' journey is a long and complicated one. It was therefore important to develop a visual language that unpacked the journey simply. To achieve this we used clean, modern graphics in an animated video and printed booklet that guided the viewer through the story simply, so that it was easy to understand.
Animated video
The content was shared with the media and placed onto Novo Nordisk's social media and digital channels.
Printed Booklet
The story of Oral Semaglutide was captured in an elegantly crafted print edition—designed for impact and distributed at select events and congresses, creating a tangible connection to cutting-edge innovation.
